|
|
|
|
|
|
Sponsored by: |
Merck |
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00449111 |
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
Condition | Intervention | Phase |
Hypertension |
Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks |
Phase III |
MedlinePlus related topics: | High Blood Pressure |
Drug Information available for: | Hydrochlorothiazide Losartan Losartan potassium Potassium chloride |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_005 |
First Received: | March 16, 2007 |
Last Updated: | March 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00449111 |
Health Authority: | Korea: Food and Drug Administration |
|
|
|
|